Provectus Pharmaceuticals' PV-10 Data to Be Presented at ESMO 2012 on October
1, 2012
Business Wire News Release
PVCT
Provectus Pharmaceuticals Inc
2012-07-17T06:04:00-04:00
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Jul. 17, 2012-- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT,
pvct.com), a development-stage oncology and dermatology biopharmaceutical company,
announced that data on PV-10 for metastatic melanoma will be presented at the ESMO 2012 (European
Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012.
Dr. Sanjiv Agarwala, M.D., Principal Investigator for the PV-10 Phase 2 trial, and Chief of Medical Oncology
and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA, will be presenting PV-10 data
included in Abstract #1137P, in a poster presentation entitled, "Immuno-chemoablation of metastatic
melanoma with intralesional rose bengal," authored by S.S. Agarwala, J.F. Thompson, B.M. Smithers, M.
Ross, B.J. Coventry, D.R. Minor, C.R. Scoggins and E. Wachter. The poster will be presented during Poster
Presentation III, in Hall XL, from 1:00 p.m. - 2:00 p.m. local time.
Dr. Craig Dees, PhD, CEO of Provectus said, “We are pleased to be accepted by ESMO, one of the most
prestigious European organizations, and look forward to reaching a global audience, as we continue in our
path towards regulatory approval of PV-10."
About ESMO
The European Society for Medical Oncology (ESMO) is the leading European professional organization,
committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to
cancer treatment and care. Since its founding in 1975 as a non-profit organization, ESMO's mission has been
to advance cancer care and cure. It achieves this through fostering and disseminating good science that
leads to better medicine and determines best practice. In this way ESMO fulfills its goal to support oncology
professionals in providing people with cancer the most effective treatments available and the high-quality
care they deserve. |
